Subscribe to RSS
DOI: 10.1055/s-0038-1646120
Effects of α2-Plasmin Inhibitor on Fibrin Clot Lysis. Its Comparison with α2-Macroglobulin
Publication History
Received 06 June 1977
Accepted 05 August 1977
Publication Date:
12 July 2018 (online)
Summary
The major plasmin inhibitors namely α2-plasmin inhibitor and α2-macroglobulin were compared for their effects on lysis of fibrin clot.
Plasmin fibrinolytic activity was immediately inhibited by α2-plasmin inhibitor, whereas α2-macroglobulin inhibited plasmin progressively. Urokinase(plasminogen activator)-induced clot lysis was inhibited efficiently by α2-plasmin inhibitor present in the clot. Inhibition of urokinase-induced clot lysis by α2-macroglobulin was weak and the molar concentration necessary for α2-macroglobulin to achieve the same degree of inhibition as that achieved with α2-plasmin inhibitor was about 10 times higher than that of α2-plasmin inhibitor.
Binding of Lys-plasminogen to fibrin was inhibited by α2-plasmin inhibitor but not by α2-macroglobulin. Molar concentrations of α2-plasmin inhibitor which were effective in inhibiting the binding were 30 times less than that of 6-aminohexanoic acid. α2-Plasmin inhibitor was found to interact with Lys-plasminogen to form a weakly-bound complex which is dissociable in the presence of 6-aminohexanoic acid, suggesting that inhibition of binding of Lys-plasminogen to fibrin by α2-plasmin inhibitor may be due to interaction of α2-plasmin inhibitor with a specific site of the plasminogen molecule and that the site may be 6-aminohexanoic acid-binding site.
It is suggested that α2-plasmin inhibitor is more reactive and efficient inhibitor of fibrinolysis than α2-macroglobulin.
-
References
- 1 Abiko Y, Iwamoto M, Tomikawa M. 1969; Plasminogen-plasmin system. V. A stoichiometric equilibrium complex of plasminogen and a synthetic inhibitor. Biochimica et biophysica acta 185: 424
- 2 Aoki N, von Kaulla KN. 1969; Inactivation of human serum plasminogen antiactivator by synthetic fibrinolysis inducers. Thrombosis et Diathesis Haemorrhagica 22: 251
- 3 Aoki N, von Kaulla KN. 1971; Human serum plasminogen antiactivator: its distinction from antiplasmin. American Journal of Physiology 220: 1137
- 4 Aoki N, Kawano T. 1972; Inhibition of plasminogen activators by naturally accuring inhibitors in man. American Journal of Physiology 223: 1334
- 5 Aoki N, Moroi M. 1974; Distinction of serum inhibitor of activator-induced clot lysis from α1-antitrypsin. Proceedings of Society for Experimental Biology and Medicine 146: 567
- 6 Aoki N, Moroi M, Matsuda M, Tachiya K. 1977; The behavior of α2-plasmin inhibitor in fibrinolytic states. Journal of Clinical Investigation 60: 361
- 7 Barlow GH, Summaria L, Robbins KC. 1969; Molecular weight studies on human plasminogen and plasmin at the microgram level. Journal of Biological Chemistry 244: 1138
- 8 Brockway WJ, Castellino FJ. 1972; Measurement of the binding of antifibrinolytic amino acids to various plasminogens. Archives of Biochemistry and Biophysics 151: 194
- 9 Camiolo SM, Thorsen S, Astrup T. 1971; Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin. Proceedings of Society for Experimental Biology and Medicine 138: 277
- 10 Collen D. 1976; Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. European Journal of Biochemistry 69: 209
- 11 Gallimore MJ. 1975; Serum inhibitors of fibrinolysis. British Journal of Haematology 31: 217
- 12 Greenwood FC, Hunter WM, Glover JS. 1963; The preparation of 131I-labelled human growth hormone of high specific radioactivity. Biochemical Journal 89: 114
- 13 Gurewich V, Hyde E, Lipinski B. 1975; The resistance of fibrinogen and soluble fibrin monomer in blood to degradation by a potent plasminogen activator derived from cadaver limbs. Blood 46: 555
- 14 Haselager EM, Goote THM, Vreeken J. 1976; Plasmin inactivation in plasma. Thrombosis and Haemostasis (Stuttg.) 35: 643
- 15 Hedner U. 1973; Studies on an inhibitor of plasminogen activation in human serum. Thrombosis et Diathesis Haemorrhagica 30: 414
- 16 Howard SM. 1966. Studies of trypsin-binding α2-macroglobulin of human plasma. Thesis, University of Southern California: Los Angeles;
- 17 Iwamoto M, Abiko Y. 1970; Preparation of α2-macroglobulin antiplasmin from human plasma. Biochimica et biophysica acta 214: 402
- 18 Kohn J. 1968. Cellulose acetate membrane electrophoresis. In: Williams CA, Chase MW. (eds.) Methods in Immunology and Immunochemistry. Academic Press; New York: Vol. 2 20
- 19 Mancini G, Carbonara AO, Heremens JF. 1965; Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 2: 235
- 20 Matsuda M, Iwanaga S, Nakamura S. 1972; A simple, large scale method for preparation of plasminogen-free fibrinogen. Thrombosis Research 1: 619
- 21 Moroi M, Moroi M, Aoki N. 1976; Isolation and characterization of α2-plasmin inhibitor from human plasma1. A novel proteinase inhibitor which inhibits activator-induced clot lysis. Journal of Biological Chemistry 251: 5956
- 22 Mollertz S, Clemmensen I. 1976; The primary inhibitor of plasmin in human plasma. Biochemical Journal 159: 545
- 23 Norman PS, Hill BM. 1958; Studies of the plasmin system. III. Physical properties of two plasmin inhibitors. Journal of Experimental Medicine 108: 639
- 24 Ogston D, Bennett B, Mackie M. 1976; Properties of a partially purified preparation of a circulating plasminogen activator. Thrombosis Research 8: 275
- 25 Remmert LF, Cohen PP. 1949; Partial purification and properties of a proteolytic enzyme of human serum. Journal of Biological Chemistry 181: 431
- 26 Robbins KC, Summaria L. 1970; Human plasminogen and plasmin. Methods in Enzymology 14: 184
- 27 Roberts RC, Riesen WA, Hall PK. 1974. Studies on the quaternary structure of human serum α2-macroglobulin. In: Fritz H, Tschesche L, Greene LJ, Truscheit E. (eds.) Proteinase Inhibitors. Bayer-Symposium V Springer-Verlag; Berlin: 63
- 28 Schultze HE, Heimburger N, Heide K, Haupt H, Stoeriko K, Schwick HG. 1963; Preparation and characterization of a1-trypsin inhibitor and α2-plasmin inhibitor of human serum. Proceedings of the 9th Congress of European Society of Haematology, Lisbon, 1315
- 29 Sjöholm I, Wiman B, Wallén P. 1973; Studies on the conformational changes of plasminogen induced during activation to plasmin and by 6-aminohexanoic acid. European Journal of Biochemistry 39: 471
- 30 Thorsen S, Glas-Greenwalt P, Astrup T. 1972; Differences in the binding to fibrin of urokinase and tissue plasminogen activator. Thrombosis et Diathesis Haemorrhagica 28: 65
- 31 Thorsen S. 1975; Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of ω-aminocarboxylic acids. Biochimica et biophysica acta 393: 55
- 32 Wallén P, Wiman B. 1972; Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen. Biochimica et biophysica acta 257: 122
- 33 Walther PJ, Steinman HM, Hill RL, McKee PA. 1974; Activation of human plasminogen by urokinase. Partial characterization of a pre-activation peptide. Journal of Biological Chemistry 249: 1173
- 34 Williams CA. 1968. Immunoelectrophoretic analysis in agar gels. In: Williams CA, Chase MW. (eds.) Methods in immunology and immunochemistry Academic Press; New York: Vol. 2 237